Literature DB >> 6937218

The effects of alkyl-lysophospholipids on leukemic cell lines. I. Differential action on two human leukemic cell lines, HL60 and K562.

T Tidwell, G Guzman, W R Vogler.   

Abstract

The action of an alkyl-lysophospholipid (ALP), ET180CH3, on clonogenicity, 3H-TdR uptake, and cell numbers was tested in two human leukemic cell lines, HL60 and K562, and short-term human leukemic bone marrow cultures. ALP eliminated clonogenicity in HL60 but not in K562 cultures; 3H-TdR uptake and cell numbers were depressed at low concentrations of ET180CH3 in HL60, but not K562 cultures. The action of the lysophospholipid analog on human leukemic bone marrow short-term cultures at low concentrations was similar to its action on HL60 cultures; clonogenicity and 3H-TdR uptake were depressed, but cell numbers were not significantly affected. The demonstration of differential action of ALP on two cell lines should significantly simplify the investigation of the mechanism of the reported differential action of ET180CH3 on normal and leukemic cell membranes.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6937218

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

1.  Laser nanothermolysis of human leukemia cells using functionalized plasmonic nanoparticles.

Authors:  Anton V Liopo; André Conjusteau; Marina Konopleva; Michael Andreeff; Alexander A Oraevsky
Journal:  Nano Biomed Eng       Date:  2012

2.  Characterization of an HL-60 cell variant resistant to the antineoplastic ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine.

Authors:  G W Small; J C Strum; L W Daniel
Journal:  Lipids       Date:  1997-07       Impact factor: 1.880

3.  Effects of hexadecylphosphocholine on protein kinase C and TPA-induced differentiation of HL60 cells.

Authors:  M Shoji; R L Raynor; E A Fleer; H Eibl; W R Vogler; J F Kuo
Journal:  Lipids       Date:  1991-02       Impact factor: 1.880

4.  Cross-resistance pattern of cell lines selected for resistance towards different cytotoxic drugs to membrane-toxic phospholipids in vitro.

Authors:  A W Himmelmann; S Danhauser-Riedl; G Steinhauser; R Busch; E J Modest; A Noseda; J Rastetter; W R Vogler; W E Berdel
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Antineoplastic activity of synthetic lysophospholipid analogs.

Authors:  W E Berdel
Journal:  Blut       Date:  1982-02

6.  Experimental studies on the role of alkyl lysophospholipids in autologous bone marrow transplantation.

Authors:  W R Vogler; A C Olson; S Okamoto; L B Somberg; L Glasser
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

7.  Response of acute myelomonocytic leukemia to alkyl-lysophospholipids. A case report.

Authors:  W E Berdel; U Fink; P A Maubach; B Permanetter; J Rastetter
Journal:  Blut       Date:  1982-03

8.  The chemotherapeutic potential of glycol alkyl ethers: structure-activity studies of nine compounds in a Fischer-rat leukemia transplant model.

Authors:  M P Dieter; C W Jameson; R R Maronpot; R Langenbach; A G Braun
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

9.  The effect of culture medium composition on ether lipid cytotoxic activity.

Authors:  L Diomede; B Piovani; E J Modest; M Salmona
Journal:  Lipids       Date:  1993-03       Impact factor: 1.880

10.  Clonogenicity of normal and malignant hematopoietic progenitor cells after exposure to synthetic alkyl-lymphospholipids.

Authors:  I Dulisch; H A Neumann; G W Löhr; R Andreesen
Journal:  Blut       Date:  1985-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.